Replies to post #4692 on VistaGen Therapeutics Inc (VTGN)

[Johnny_C]

I am not sure if it is to post the whole research report as it goes to people paying for the service.

Long and short they have an $8.00 target and $1.5 bil valuation just based on the SAD drug.

Patiently waiting for them to announce enrollment and then dosing.


If AV-101 also comes in with good phase 2 as early as Q1 things will get very interesting.